eXoZymes (EXOZ) Stock Price, News & Analysis

Company Overview

eXoZymes, Inc. develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide. Headquartered in the United States, the company distributes its products through direct sales and a global network of distributors, positioning itself to support growth in both research and diagnostic markets.

Key Stats

• Today's Range: $13.50 to $13.50
• 50-Day Range: $9.31 to $15.48
• 52-Week Range: $8.50 to $23.99
• Volume: 966 shs
• Average Volume: 3,107 shs
• Market Capitalization: $113.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

eXoZymes Stock Analysis - MarketRank™

eXoZymes scored higher than 18% of companies evaluated by MarketBeat, and ranked 840th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for eXoZymes.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

eXoZymes has a P/B Ratio of 10.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of eXoZymes has been sold short.

Short Interest Ratio / Days to Cover

eXoZymes has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in eXoZymes has recently decreased by 8.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

eXoZymes does not currently pay a dividend.

Dividend Growth

eXoZymes does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.76% of the float of eXoZymes has been sold short.

Short Interest Ratio / Days to Cover

eXoZymes has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in eXoZymes has recently decreased by 8.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.65

News Sentiment

eXoZymes has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for eXoZymes this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, eXoZymes insiders have not sold or bought any company stock.

Percentage Held by Insiders

72.41% of the stock of eXoZymes is held by insiders. A high percentage of insider ownership can be a sign of company health.

EXOZ Stock Analysis - Frequently Asked Questions

How have EXOZ shares performed this year?

eXoZymes' stock was trading at $17.39 at the start of the year. Since then, EXOZ shares have decreased by 22.4% and is now trading at $13.50.

How were eXoZymes' earnings last quarter?

eXoZymes Inc. (NASDAQ:EXOZ) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.28) earnings per share for the quarter.
Read the conference call transcript.

How do I buy shares of eXoZymes?

Shares of EXOZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EXOZ
• CIK: 2010788
• Web: N/A
• Phone: (626) 415-1488
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.50%
• Return on Assets: -81.63%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 6.19
• Quick Ratio: 6.19

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 1,618.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: 10.80

Miscellaneous

• Outstanding Shares: 8,390,000
• Free Float: 2,314,000
• Market Cap: $113.27 million
• Optionable: N/A
• Beta: N/A